- Home
- IOVA vs DAVA Comparison
IOVA vs DAVA Comparison
Compare IOVA & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- DAVA
- Stock Information
- Founded
- IOVA 2007
- DAVA 2000
- Country
- IOVA United States
- DAVA United Kingdom
- Employees
- IOVA N/A
- DAVA N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- DAVA EDP Services
- Sector
- IOVA Health Care
- DAVA Technology
- Exchange
- IOVA Nasdaq
- DAVA Nasdaq
- Market Cap
- IOVA 771.4M
- DAVA 827.6M
- IPO Year
- IOVA N/A
- DAVA 2018
- Fundamental
- Price
- IOVA $1.88
- DAVA $13.72
- Analyst Decision
- IOVA Buy
- DAVA Buy
- Analyst Count
- IOVA 10
- DAVA 8
- Target Price
- IOVA $12.22
- DAVA $26.75
- AVG Volume (30 Days)
- IOVA 10.4M
- DAVA 800.9K
- Earning Date
- IOVA 08-07-2025
- DAVA 05-14-2025
- Dividend Yield
- IOVA N/A
- DAVA N/A
- EPS Growth
- IOVA N/A
- DAVA N/A
- EPS
- IOVA N/A
- DAVA 0.40
- Revenue
- IOVA $212,679,000.00
- DAVA $1,007,631,882.00
- Revenue This Year
- IOVA $86.62
- DAVA $6.33
- Revenue Next Year
- IOVA $69.95
- DAVA N/A
- P/E Ratio
- IOVA N/A
- DAVA $35.42
- Revenue Growth
- IOVA 11070.12
- DAVA 5.95
- 52 Week Low
- IOVA $1.64
- DAVA $13.39
- 52 Week High
- IOVA $12.51
- DAVA $34.94
- Technical
- Relative Strength Index (RSI)
- IOVA 47.47
- DAVA 35.26
- Support Level
- IOVA $1.68
- DAVA $14.69
- Resistance Level
- IOVA $2.02
- DAVA $15.89
- Average True Range (ATR)
- IOVA 0.11
- DAVA 0.65
- MACD
- IOVA 0.03
- DAVA -0.04
- Stochastic Oscillator
- IOVA 61.42
- DAVA 12.41
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About DAVA Endava plc (each representing one)
Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.